Pharmaceutical Research and Development

Nexien BioPharma is proceeding with pre-clinical and clinical drug development activities, in accordance with U.S. Food and Drug Administration ("FDA") protocols, for a number of pharmaceutical formulations that include cannabinoids.

You are here: Home About Us

Nexien’s Drug Development Activities

Nexien is developing advanced parenteral formulations and drug delivery systems, as well as precision oral and sublingual tablet technology for the use of cannabinoid API's as standalone or adjunct therapies.

Nexien BioPharma’s drug development strategy consists of:

The treatment of convulsive disorders, particularly epilepsy and refractory epilepsy. Cannabinoid treatments have shown efficacy in epilepsy conditions which do not respond well to the current standard of care.
The acute treatment during exposure to organophosphorus nerve agents , including sarin gas.
The treatment of various symptoms related to myotonic and muscular diseases such as dystrophia diseases.